Curis (NASDAQ:CRIS) Issues Quarterly Earnings Results

Curis (NASDAQ:CRIS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.36), RTT News reports. Curis had a negative net margin of 468.18% and a negative return on equity of 243.03%. The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $2.20 million. During the same quarter last year, the company posted ($2.40) earnings per share.

Curis Stock Performance

CRIS stock traded up $0.06 during mid-day trading on Friday, hitting $5.00. The company had a trading volume of 24,493 shares, compared to its average volume of 27,781. The firm has a market cap of $29.45 million, a PE ratio of -0.58 and a beta of 3.35. Curis has a 12 month low of $3.80 and a 12 month high of $17.49. The stock’s fifty day moving average price is $7.58 and its two-hundred day moving average price is $10.53.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Truist Financial reiterated a “buy” rating and set a $26.00 price objective on shares of Curis in a research report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Curis in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Curis in a research note on Wednesday, May 15th.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.